Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Beam Therapeutics (BEAM) Income towards Parent Company: 2019-2024

Historic Income towards Parent Company for Beam Therapeutics (BEAM) over the last 6 years, with Dec 2024 value amounting to -$376.8 million.

  • Beam Therapeutics' Income towards Parent Company fell 16.61% to -$112.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$421.8 million, marking a year-over-year decrease of 191.13%. This contributed to the annual value of -$376.8 million for FY2024, which is 184.25% down from last year.
  • Beam Therapeutics' Income towards Parent Company amounted to -$376.8 million in FY2024, which was down 184.25% from -$132.6 million recorded in FY2023.
  • Beam Therapeutics' Income towards Parent Company's 5-year high stood at -$132.6 million during FY2023, with a 5-year trough of -$376.8 million in FY2024.
  • In the last 3 years, Beam Therapeutics' Income towards Parent Company had a median value of -$263.6 million in 2022 and averaged -$257.7 million.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first soared by 49.71% in 2023, then tumbled by 184.25% in 2024.
  • Over the past 5 years, Beam Therapeutics' Income towards Parent Company (Yearly) stood at -$194.6 million in 2020, then tumbled by 90.47% to -$370.6 million in 2021, then grew by 28.88% to -$263.6 million in 2022, then spiked by 49.71% to -$132.6 million in 2023, then tumbled by 184.25% to -$376.8 million in 2024.